low-to-moderate - Medical device demand is relatively non-discretionary as procedures address acute clinical needs (vascular access for hospitalized patients, emergency airway management). However, elective procedures like UroLift for BPH are moderately sensitive to consumer confidence and employment-linked insurance coverage. Hospital capital budgets for equipment purchases tighten during recessions, though disposables revenue remains stable. Estimated 60-70% of revenue is non-discretionary procedural volumes.

Rising rates moderately impact Teleflex through higher borrowing costs on its $3.5B debt (0.72 D/E ratio), increasing interest expense and pressuring net margins. Additionally, higher rates compress valuation multiples for med-tech stocks as investors demand higher risk premiums. However, the company's 10.5% FCF yield provides downside support. Demand-side impact is minimal as healthcare spending is relatively rate-insensitive, though hospital system financing costs for capital equipment may slow adoption.

value - The stock trades at 1.5x sales and 1.3x book with 10.5% FCF yield despite -35% one-year return, attracting value investors betting on operational turnaround and margin recovery. Negative ROE and compressed margins suggest distressed valuation, appealing to special situations investors. Not a growth stock given 2.4% revenue growth, nor dividend play given focus on debt paydown. Turnaround thesis centers on restoring profitability to historical levels.